Derma Sciences (DSCI) Scheduled to Post Quarterly Earnings on Thursday
Derma Sciences (NASDAQ:DSCI) is scheduled to be issuing its quarterly earnings data on Thursday, August 7th. Parties interested in participating in the company’s conference call can do so using this link.
Derma Sciences (NASDAQ:DSCI) last announced its earnings results on Thursday, May 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.14. The company had revenue of $19.80 million for the quarter, compared to the consensus estimate of $19.79 million. On average, analysts expect Derma Sciences to post $-1.89 EPS for the current fiscal year and $-1.21 EPS for the next fiscal year.
Derma Sciences (NASDAQ:DSCI) opened at 9.69 on Wednesday. Derma Sciences has a 1-year low of $8.45 and a 1-year high of $15.51. The stock has a 50-day moving average of $10.63 and a 200-day moving average of $11.35. The company’s market cap is $244.0 million.
Several analysts have recently commented on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Derma Sciences in a research note on Wednesday, June 18th. They now have a $19.00 price target on the stock, up previously from $18.00. Finally, analysts at Oppenheimer reiterated an “outperform” rating on shares of Derma Sciences in a research note on Friday, May 9th. They now have a $19.00 price target on the stock, down previously from $21.00. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Derma Sciences has a consensus rating of “Hold” and a consensus price target of $17.03.
Derma Sciences, Inc (NASDAQ:DSCI), is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.